Printer Friendly


 SAN DIEGO, Sept 27 /PRNewswire/ -- Cytoprobe Corp. (NASDAQ: CYTP) (the "company") today announced that Dartmouth-Hitchcock Medical Center, in cooperation with Scientific Atlanta Inc., will begin human clinical trials of the company's non-invasive Intracranial Pressure Measurement Device ("ICP device") on Oct. 2, 1993. Presently, ICP measurement involves drilling a hole in the skull and the insertion of a filled catheter through the hole and into the cranial cavity. These trials will be conducted at Dartmouth under the direction of Dr. Richard Saunders, chairman of the Department of Neurosurgery, and will continue for 60 to 90 days.
 The company also announced the appointment of Henry Teague Jr. and William Spencer to its board of directors. Teague has extensive management experience in a wide range of businesses. His operational expertise should prove invaluable to the board in the company's transition from development to operations. Spencer is experienced in internal audit, finance and all phases of brokerage operations. He brings to the board both a practical and planning perspective.
 Cytoprobe Corp. operates two primary businesses: the development, manufacturing and marketing of specialty medical devices and the exploration, development and production of oil and gas reserves. For further information call 619-689-9400.
 -0- 9/27/93
 /CONTACT: Cytoprobe Corp., 619-689-9400/

CO: Cytoprobe Corp. ST: California IN: HEA SU:

NY-EH -- LA015 -- 5927 09/27/93 12:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 27, 1993
Previous Article:/C O R R E C T I O N -- GO VIDEO INC./

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters